Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin vs ALLR3 induction for pediatric first-relapse high-risk B-cell precursor ALL
NL-OMON60994Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Pfizer. Primary endpoint: Primary efficacy endpoint. Started Aug 2023; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON60994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60994.